Synthetic Biology Startup Funding 2025-2026
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
This report analyzes publicly disclosed equity rounds raised by pure-play synthetic biology companies from August 2025 through September 2026, using a $300K minimum, an over-80% pure-play threshold, and source-qualified disclosed amounts. The resulting sample contains 24 deals across 24 unique companies and approximately $1.236B of disclosed capital.
Fundraising in the synthetic biology market is active but highly concentrated. The largest deal represents 35.18% of all disclosed capital, while the top 3 deals account for 56.13% and the top 10 reach 87.14%.
The average synthetic biology round is $51.52M, but the median is only $20.55M. That roughly 2.5x gap shows how heavily a small group of large financings pulls the market average upward.
Deal flow averages 1.71 rounds per calendar month, with a median of one deal per month. Capital averages $88.32M per month, but the monthly dollar figures are much more volatile than financing frequency.
Synthetic Biology Therapeutics dominates the synthetic biology market with $824.10M across 6 deals. The category captures 66.65% of capital from only 25% of disclosed transactions.
North America is the clear capital center of the synthetic biology market. It accounts for 11 deals and $945.40M, representing 76.46% of disclosed capital despite producing less than half of deal activity.
The synthetic biology market remains active at early stages, but most dollars go to mature companies. Seed plus Series A represents 62.5% of deals yet only 27.83% of disclosed capital, while late-stage rounds absorb 70.88%.
Large rounds materially shape every market-level headline. Removing the seven financings strictly above $50M leaves only $273.05M, meaning roughly 78% of all disclosed capital comes from those seven transactions.
Follow-on financing dominates the dataset. Twenty of the 24 qualifying rounds are clearly follow-ons, while only four are described as first or first major disclosed financings, showing that capital largely favors companies with prior validation.
Repeat investors are surprisingly scarce. SOSV appears in three qualifying rounds, while daphni and Janus Henderson Investors appear twice each, suggesting financing remains spread across many specialized syndicates.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
What are all the funding deals in the synthetic biology market from August 2025 to September 2026?
The table below lists every qualifying disclosed equity round in the synthetic biology market from August 2025 through September 2026. We define the synthetic biology market as tools, platforms, and products that rely on engineering biological systems using designed DNA, genetic circuits, or engineered organisms.
Each row shows the company, what it does, its category, the announcement month, funding stage, round size, region, and main investors. For a wider view of the companies, technologies, and funding patterns shaping this industry, see our Synthetic Biology market report.
| Company | What they do | Category | Date | Stage | Deal size | Region | Main investors |
|---|---|---|---|---|---|---|---|
| Strand Therapeutics | Programmable mRNA therapeutics using genetic circuits to control therapeutic payload expression in specific cellular environments | Synthetic Biology Therapeutics | Aug 2025 | Series B | $153M | North America | Not disclosed in supplied source |
| Scindo | AI and experimental platform for discovering and engineering enzymes that convert renewable feedstocks into ingredients and chemicals | Synbio Design Software | Sep 2025 | Seed | $5.4M | Europe | Kadmos Capital; Clay Capital; PINC; Synbioven; AgFunder; SOSV; Farvatn Venture; Savantus Ventures |
| Ansa Biotechnologies | Enzymatic DNA synthesis platform producing complex and long sequence-perfect DNA for engineered-biology workflows | Biofoundry Platforms | Oct 2025 | Series B | $54.4M | North America | Cerberus Ventures; Blue Water Life Science Advisors; Altitude Life Science Ventures; Fall Line Capital; AIM13; Black Opal Ventures |
| Biocentis | Genetically engineers insect populations to reduce reproduction and control disease vectors and agricultural pests | Engineered Microbes | Nov 2025 | Seed | $13M | Europe | Not disclosed in supplied source |
| Profluent | Generative biological models that design programmable proteins, genome editors, antibodies, and enzymes from desired functional specifications | Synbio Design Software | Nov 2025 | Series A | $106M | North America | Not disclosed in supplied source |
| bit.bio | Programs human induced pluripotent stem cells into defined cell types using its opti-ox transcription-factor engineering system | Biofoundry Platforms | Jan 2026 | Series C | $50M | Europe | M&G Investments |
| Think Bioscience | Uses synthetic biology and high-throughput functional surveys to identify biochemical footholds for difficult drug targets | Synthetic Biology Therapeutics | Jan 2026 | Series A | $55M | North America | Regeneron Ventures; Innovation Endeavors; Janus Henderson Investors; T.A. Springer; CE-Ventures; MBX Capital; YK Bioventures; AV8 Ventures; CU Innovations; Buff Gold Ventures |
| Octarine Bio | Engineers microbial cell factories and enzymatic systems to manufacture precision-fermented pigments for textiles, food, and other applications | Synbio Materials Platforms | Jan 2026 | Series A | $5.8M | Europe | The Footprint Firm; Unconventional Ventures; Edaphon; DSM-Firmenich Ventures; Oskare Capital |
| Antheia | Engineers yeast and biosynthetic pathways to manufacture complex pharmaceutical ingredients difficult to obtain through agriculture or chemistry | Engineered Microbes | Jan 2026 | Series C | $24M | North America | ATHOS KG; America's Frontier Fund; GHIC |
| baCta | Combines AI, genome engineering, and an automated precision biofoundry to create microbial strains producing high-value molecules | Engineered Microbes | Mar 2026 | Seed | $8.3M | Europe | LocalGlobe; daphni; OVNI Capital |
| Epoch Biodesign | Uses engineered enzymes and AI-guided biodesign to depolymerize difficult plastic waste into useful chemical inputs | Synbio Materials Platforms | Mar 2026 | Unknown | $12M | Europe | Extantia; Kompas; Happiness Capital; lululemon; Leitmotif |
| Cauldron Ferm | Develops continuous hyper-fermentation infrastructure designed to maintain engineered microbes at high productivity | Biofoundry Platforms | Mar 2026 | Series A | $13.25M | Asia-Pacific | Main Sequence Ventures; Horizons Ventures; SOSV; NGS Super |
| Scala Biodesign | Computational protein-design platform combining language models, physics, and evolutionary data to design and optimize proteins | Synbio Design Software | Mar 2026 | Series A | $16M | Middle East | Grove Ventures; TLV Partners; Deep Insight |
| Generare | Mines microbial genomes and uses synthetic-biology workflows to discover, express, and characterize previously unknown natural molecules | Synbio Design Software | Apr 2026 | Series A | $23.2M | Europe | Alven; daphni; Galion.exe; Teampact Ventures; VIVES Partners |
| AuX Labs | Engineers microorganisms through precision fermentation to manufacture functional dairy proteins for cheese | Synbio Food Platforms | Apr 2026 | Unknown | $4M | North America | NYA Ventures; Nàdarra Ventures; Verdex Capital; Builders VC; Congruent Ventures; Bluestein Ventures |
| Fermeate | Uses optogenetics to control gene expression in engineered production organisms during industrial fermentation | Engineered Microbes | Apr 2026 | Seed | $2M | North America | Newfund Capital; SOSV; Ajinomoto Group Ventures; Ki Tua Fund; Heuristic Capital Partners; Momentum Capital; Plug and Play; Tesserakt Ventures; Ag Startup Engine |
| Pumpkinseed | Builds a nanophotonic protein-sequencing system that generates large functional proteomic datasets for biological AI and biopharma | Synbio Design Software | May 2026 | Series A | $20M | North America | NfX; Future Ventures; Base4; ADVentures; Stanford |
| Melazyme | Develops proprietary precision-fermentation systems for functional biomolecules across food and other industries | Synbio Food Platforms | May 2026 | Seed | $2M | North America | SeaX Ventures; Stellaris Venture Partners; Plug and Play Ventures |
| StrainX Bioworks | Synthetic-biology and precision-fermentation platform engineering production strains and processes for high-value ingredients | Synbio Food Platforms | May 2026 | Series A | $13M | Asia-Pacific | Prime Venture Partners; Leo Capital; Good Startup; Sparrow Capital; Sun Icon Ventures; Dholakia Ventures; WindT Angels |
| YolTech Therapeutics | Develops in-vivo gene-editing medicines combining engineered editors with non-viral LNP delivery | Synthetic Biology Therapeutics | May 2026 | Series C | $70M | Asia-Pacific | Loyal Valley Capital; new and existing shareholders |
| NewLimit | Designs combinations of transcription factors and biological regulators to epigenetically reprogram aged cells toward younger functional states | Synthetic Biology Therapeutics | Jun 2026 | Series C | $435M | North America | Founders Fund; Thrive Capital; Lilly Ventures; Nat Friedman; Daniel Gross |
| Telum Therapeutics | Uses metagenomic datasets, synthetic biology, and generative AI to engineer protein-based antimicrobial therapies | Synthetic Biology Therapeutics | Jul 2026 | Series A | $21.1M | Europe | AMR Action Fund; Inveready; Invivo Partners; CDTI/SICC Innvierte; Clave Capital; Sodena |
| Epicrispr Biotechnologies | Engineers programmable epigenetic gene-regulation systems that switch disease-associated genes on or off without permanently rewriting DNA | Synthetic Biology Therapeutics | Aug 2026 | Series C | $90M | North America | Octagon Capital; Janus Henderson Investors; Fidelity Management & Research; Cormorant; Duquesne Family Office; Sanofi Ventures; abrdn; Angelini Ventures; Readout Capital |
| Adaptyv Biosystems | Automated wet-lab platform combining cell-free synthetic biology, nanofluidics, and machine learning to validate AI-designed proteins | Biofoundry Platforms | Aug 2026 | Series A | $40M | Europe | Highland Europe; ACE Ventures; byFounders; Y Combinator |
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this synthetic biology funding tracker by reviewing publicly disclosed equity rounds announced from August 2025 through September 2026. A company counts as pure-play when more than 80% of its activity is dedicated to tools, platforms, or products where modern synthetic biology is central to how the technology is designed, produced, or performs.
We applied four core filters. We included equity rounds only, required a disclosed value of at least $300K, kept only companies meeting the more-than-80% pure-play standard, and required confirmation from a direct company announcement, transaction press release, or tier-1 publication with the underlying source URL preserved.
Grants, debt, acquisitions, non-separable grant-and-equity packages, and transactions without a sufficiently precise equity amount were removed from the quantitative dataset. Cellarim Labs was excluded because available reports gave conflicting round values without a definitive source-qualified amount, while SynMetabio and NewPro Bioworks were excluded because their announced financing sizes were too imprecise for dollar-level aggregation.
Standing Ovation and Immitra Bio were also removed because non-dilutive components could not be cleanly separated from their headline financing packages. Serapha Bio was excluded because its financing was linked to a reverse-merger transaction and included committed capital, making it materially less comparable with the closed private equity rounds used here.
The final dataset contains 24 disclosed rounds across 24 unique companies and approximately $1.236B of qualifying capital. Every average, median, stage share, category share, geographic split, and concentration figure in this article is calculated on that disclosed sample.
How active has fundraising been in the synthetic biology market?
As of September 2026, fundraising in the synthetic biology market has remained active over the past 12 months, with 24 qualifying disclosed equity rounds totaling approximately $1.236B. Deal flow averages 1.71 financings per calendar month, while the median month contains one deal.
The number of financings is more stable than the amount of capital deployed. Average monthly capital is $88.32M, but the median is $51.98M because individual large rounds create substantial swings.
Removing the seven rounds strictly above $50M changes the picture sharply. Only $273.05M remains, so approximately 78% of disclosed synthetic biology capital comes from seven financings.
That means monthly dollar totals should not be read as a smooth measure of market health. Deal-count cadence is more useful when judging whether financing appetite is broadening across the synthetic biology market.
For a deeper view of the companies and financing patterns behind this activity, see our synthetic biology market funding report.
How concentrated has fundraising been in the synthetic biology market?
As of September 2026, fundraising in the synthetic biology market has been highly concentrated over the past 12 months. The largest transaction represents 35.18% of all disclosed capital, while the top 3 deals account for 56.13% and the top 5 reach 69.07%.
NewLimit's $435M Series C is the largest financing in the dataset. Strand Therapeutics follows at $153M, while Profluent raised $106M.
The top 10 financings together represent 87.14% of every disclosed dollar. That leaves less than 13% of aggregate capital for the other 14 qualifying transactions.
This concentration makes headline totals difficult to interpret without looking underneath them. A strong aggregate quarter can reflect only a handful of companies rather than easier financing conditions across synthetic biology.
How much of the synthetic biology funding signal is driven by outliers?
As of September 2026, a large part of the synthetic biology funding signal is driven by outliers over the past 12 months. Seven deals are strictly above $50M, yet those financings account for approximately 78% of disclosed capital.
The skew also appears in the difference between average and median round size. The average is $51.52M, while the median is $20.55M, making the mean roughly 2.5 times higher.
Only three rounds exceed $100M: NewLimit at $435M, Strand Therapeutics at $153M, and Profluent at $106M. Those three alone account for 56.13% of total capital.
The best reading rule is therefore to benchmark a typical synthetic biology financing against the median, not the mean. Market averages substantially overstate the capital available to an ordinary company.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Is the synthetic biology market broad with many targets, or narrow with few fundable companies?
As of September 2026, the synthetic biology market has a reasonably broad set of funded companies but a narrow distribution of capital over the past 12 months. All 24 qualifying deals were raised by 24 different companies, so no single company repeatedly inflated deal count during the period.
Company activity is spread across six categories. Synthetic Biology Therapeutics leads with 6 deals, followed by Synbio Design Software with 5 and both Biofoundry Platforms and Engineered Microbes with 4 each.
The breadth disappears when looking at dollars. Five companies absorb 69.07% of disclosed capital, while the top 10 account for 87.14%.
This means the synthetic biology market offers multiple investable technical approaches, but only a small subset currently receives very large checks. Breadth of company formation should not be confused with breadth of capital availability.
Is synthetic biology mostly an early-stage formation market or a late-stage scaling market?
As of September 2026, the synthetic biology market combines broad early-stage formation with late-stage capital concentration over the past 12 months. Seed plus Series A represents 15 of 24 deals, or 62.5%, but receives only 27.83% of disclosed capital.
Late-stage rounds defined as Series B, Series C, Series D+, and Growth Equity account for $876.40M, or 70.88% of total capital. Unknown-stage financings contribute another $16M, or 1.29%.
Series C alone absorbs $669M and 54.11% of total synthetic biology funding from only five deals. By contrast, Seed accounts for five deals but just $30.70M, or 2.48% of capital.
The pattern shows that new company formation remains alive, while expensive capital is reserved for companies that have crossed more validation gates. For more context on where those financing stages sit inside the market, see our analysis of the synthetic biology market.
Which categories attract the most investor attention in synthetic biology?
As of September 2026, Synthetic Biology Therapeutics attracts the most investor attention in the synthetic biology market over the past 12 months. The category recorded 6 deals and $824.10M, representing 25% of deal activity and 66.65% of disclosed capital.
Synbio Design Software is the second-largest category by capital with $170.60M across 5 deals. Biofoundry Platforms follows with $157.65M across 4 transactions.
Engineered Microbes produced 4 deals but only $47.30M, while Synbio Food Platforms generated 3 deals and $19M. Synbio Materials Platforms recorded 2 deals totaling $17.80M.
The deal-count split shows investor interest extending well beyond therapeutics, but the dollar split shows where conviction is deepest. We examine these category differences further in our full synthetic biology market report.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Which categories attract disproportionately large checks in the synthetic biology market?
As of September 2026, Synthetic Biology Therapeutics attracts disproportionately large checks in the synthetic biology market over the past 12 months. Its capital-share-to-deal-share ratio is 2.67x, by far the highest of any category.
The therapeutic category's average round is $137.35M and its median is $80M. Those numbers remain elevated even beyond the $435M NewLimit outlier because Strand, Epicrispr, YolTech, and Think Bioscience also raised substantial rounds.
Biofoundry Platforms sits much closer to parity at 0.77x, with a $39.41M average and $45M median. Synbio Design Software has a 0.66x ratio, reflecting a wider spread between smaller platform financings and Profluent's $106M round.
Engineered Microbes, Materials, and Food all sit well below parity at 0.23x, 0.17x, and 0.12x respectively. Those categories generate company activity, but investors currently fund them with materially smaller checks.
Which geographies matter most for fundraising in the synthetic biology market?
As of September 2026, North America matters most for fundraising in the synthetic biology market over the past 12 months. The region accounts for $945.40M across 11 deals, representing 76.46% of disclosed capital and 45.83% of deal activity.
Europe is much closer to North America in company activity than in dollars. It produced 9 deals, or 37.5% of the dataset, but attracted only $178.80M and 14.46% of disclosed capital.
Asia-Pacific contributed 3 deals and $96.25M, while the Middle East contributed one $16M transaction. Latin America and Africa produced no qualifying disclosed rounds under the applied filters.
Check size explains much of the regional divergence. North America's median round is $54.40M versus $13M in Europe, making the typical North American financing more than four times larger. For a deeper regional view, see our synthetic biology market report covering global funding.
Is the synthetic biology opportunity set broad or concentrated in one hub?
As of September 2026, the synthetic biology opportunity set is geographically concentrated rather than evenly global over the past 12 months. North America and Europe together represent 20 of 24 deals and approximately 90.92% of disclosed capital.
North America alone captures more than three quarters of every disclosed dollar. Its capital share of 76.46% is substantially higher than its 45.83% share of transactions.
Europe shows the opposite structure, producing 37.5% of deals but only 14.46% of capital. The region therefore has meaningful company formation without comparable financing depth.
Asia-Pacific remains visible but small at 7.78% of capital, while the Middle East accounts for 1.29%. The absence of qualifying Latin American and African rounds indicates limited publicly visible venture depth under these strict filters.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Is synthetic biology a market of small experiments or scaled financings?
As of September 2026, the synthetic biology market contains both small technical-validation rounds and scaled financings over the past 12 months. The median disclosed round is $20.55M, while eight of 24 transactions are $50M or larger.
Three deals are below $5M, eight fall between $5M and under $20M, and five sit between $20M and under $50M. Another eight rounds reach at least $50M.
Seven deals are strictly above $50M, representing 29.17% of transaction count. Three exceed $100M, or 12.5% of all qualifying financings.
The $51.52M average therefore should not be treated as a typical synthetic biology check. The $20.55M median better reflects the center of the distribution. For more detail on funding benchmarks and market structure, see our synthetic biology funding market deck.
Who are the investors that appear the most in synthetic biology fundraising?
As of September 2026, only three clearly verified investors appear in more than one qualifying synthetic biology financing over the past 12 months. SOSV leads with participation in three deals, while daphni and Janus Henderson Investors each appear twice.
SOSV participated in Scindo, Cauldron Ferm, and Fermeate. Its activity is concentrated in enabling and industrial biology rather than the dataset's largest therapeutic financings.
daphni appears in baCta and Generare, linking microbial engineering with biological discovery platforms. Janus Henderson appears in Think Bioscience and Epicrispr Biotechnologies, both within therapeutics.
The limited repetition suggests the synthetic biology market is financed by many specialized syndicates rather than a small closed circle of dominant investors. Investor counts also measure participation, not individual dollars, because round announcements rarely disclose each investor's exact contribution.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
INSIGHTS
The insights below come from reviewing 24 qualifying disclosed synthetic biology equity rounds announced from August 2025 through September 2026. They focus on the recurring patterns that help interpret future financings rather than simply restating individual transactions.
- The synthetic biology market operates under two different capital regimes. Therapeutics receives long-runway financing, while industrial, food, and materials companies are funded around technical and commercialization milestones.
- The $1.236B headline substantially overstates financing conditions for a typical synthetic biology startup. Removing seven rounds above $50M leaves only $273.05M across the rest of the market.
- The median round is more decision-useful than the average. A $20.55M median versus a $51.52M mean shows how severely a few large financings distort market benchmarks.
- Therapeutics captures 66.65% of capital from only 25% of deals. That premium survives the NewLimit outlier because several other therapeutic companies also raised $55M to $153M.
- Series A is the clearest breadth signal in the synthetic biology market. It represents 41.67% of deals but only 25.34% of capital, showing broad institutional formation beneath the headline megarounds.
- Series C tells the opposite story. Five financings absorb 54.11% of disclosed capital, so capital concentration is closely tied to maturity and validation.
- Seed plus Series A represents 62.5% of deals but only 27.83% of dollars. New ventures continue forming, but investors reserve the largest checks for companies that have already passed multiple proof points.
- Seed financing remains relatively capital-efficient despite synthetic biology's capital-intensive reputation. The median Seed round is only $5.4M, indicating that early technical validation can still be financed incrementally.
- Biofoundry Platforms show the strongest non-therapeutic financing depth. Their $45M median exceeds the $39.41M average, indicating relatively consistent checks rather than dependence on one giant round.
- Synbio Design Software contains two financing regimes. Most rounds sit around $5M to $23M, while Profluent demonstrates that foundational biological-design platforms can attract therapeutic-scale capital.
- Food synthetic biology shows company formation without equivalent capital depth. It represents 12.5% of deals but only 1.54% of dollars, giving it a 0.12x capital-share-to-deal-share ratio.
- Materials companies face a similar financing constraint. Investors appear willing to fund demonstration and manufacturing milestones, but not yet large capacity expansions across the category.
- The strongest predictor of check size is not the nominal funding stage. Evidence such as clinical progress, programmable biological control, platform adoption, or credible production scale matters more.
- North America wins on financing depth rather than company-count dominance. It generates 45.83% of deals but captures 76.46% of disclosed capital.
- Europe has nearly as much deal activity as North America but far less capital. Its $13M median round versus North America's $54.40M median indicates a structural check-size gap.
- Asia-Pacific's $32.08M average is misleading beside its $13.25M median. YolTech's $70M financing materially lifts a regional sample containing only three qualifying deals.
- Monthly dollar totals are a weak standalone measure of synthetic biology market health. June 2026 looks exceptional because one $435M NewLimit financing dominates the month.
- Deal-count cadence gives a cleaner signal of ecosystem breadth. Months containing several independent financings provide stronger evidence of investor appetite than months dominated by one megaround.
- Repeat investors are uncommon across the qualifying dataset. That fragmentation suggests specialized technical syndicates remain important and no small investor group controls visible synthetic biology financing.
- SOSV's three appearances are concentrated in enabling and industrial biology. Its repeat activity therefore signals appetite for technical-platform risk rather than participation in late-stage therapeutic concentration.
- Strict source hygiene materially changes the apparent market. Separating grants from equity and rejecting imprecise headline amounts prevents funding totals from systematically overstating investable private capital.
Forbes (Strand Therapeutics), Scindo (Seed financing), Business Wire (Ansa Biotechnologies), Imperial College London (Biocentis), Forbes (Profluent), bit.bio (Series C), PR Newswire (Think Bioscience), Antheia (Series C close), baCta (Seed financing), Cauldron Ferm (Series A), Axios (Scala Biodesign), Alven (Generare), GlobeNewswire (AuX Labs), Pumpkinseed Bio (Series A), The Economic Times (StrainX Bioworks), YolTech Therapeutics (Series C), STAT (NewLimit), Telum Therapeutics (Series A), Epicrispr Biotechnologies (Series C), Greater Geneva Bern area (Adaptyv Biosystems)
Related blog posts
- The main fundraising trends in synthetic biology
- The startups that have raised the most funding in synthetic biology
- The evolution of funding activity in synthetic biology
